financetom
Business
financetom
/
Business
/
Why Tenon Medical (TNON) Shares Are Getting Hammered
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Tenon Medical (TNON) Shares Are Getting Hammered
Mar 26, 2025 8:55 AM

Tenon Medical Inc ( TNON ) shares are trading lower by 32.0% to $2.55 during Wednesday’s session after the company announced pricing of $2.5 million registered direct offering at $2.00.

What To Know: Tenon Medical ( TNON ) has entered a securities purchase agreement with a healthcare-focused institutional investor, raising approximately $2.5 million. The deal includes a registered direct offering of 1,271,500 shares of common stock at $2.00 per share.

Additionally, in a concurrent private placement, Tenon will issue warrants for an equal number of shares at the same price, exercisable immediately and expiring in five years. The offering is expected to close by March 27, pending customary conditions.

A.G.P./Alliance Global Partners is the sole placement agent. Tenon says the company plans to use the proceeds for working capital and general corporate purposes.

Read Also: GameStop Stock Is Surging Wednesday: What’s Going On?

How To Buy TNON Stock

By now you're likely curious about how to participate in the market for Tenon Medical ( TNON ) – be it to purchase shares, or even attempt to bet against the company.

Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy “fractional shares,” which allows you to own portions of stock without buying an entire share.

If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to “go short” a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.

According to data from Benzinga Pro, TNON has a 52-week high of $15.79 and a 52-week low of $1.09.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Smithfield Foods reports 20% drop in hog output
Smithfield Foods reports 20% drop in hog output
Oct 3, 2024
Sept 27 (Reuters) - Smithfield Foods has reduced its hog production by about 20% by cutting farm operations in multiple U.S. states, the world's largest pork processor said on Friday. The company did not immediately respond to a Reuters request for comment on over what period of time the production had fallen 20%. Earlier this year, the Virginia-based firm announced...
Learning Technologies likely to recommend General Atlantic's proposed takeover offer
Learning Technologies likely to recommend General Atlantic's proposed takeover offer
Oct 3, 2024
Sept 27 (Reuters) - Learning Technologies Group on Friday confirmed that the U.S. private equity investor General Atlantic has approached it with a possible cash offer to acquire the corporate education group. Learning Technologies said it was minded to recommend the proposed offer of 100 pence per LTG share and has provided access to confirmatory due diligence to General Atlantic....
Factbox-What might a combination of UniCredit and Commerzbank look like?
Factbox-What might a combination of UniCredit and Commerzbank look like?
Oct 3, 2024
MILAN (Reuters) - Executives from UniCredit and Commerzbank held their first meeting on Friday, after the Italian bank this month emerged as the biggest investor in its German peer with a nearly 21% stake, subject to supervisory approval. At 61 billion euros ($68 billion), UniCredit's market value is roughly three times Commerzbank's 19 billion euros. Shares in Germany's second-biggest publicly-listed...
Lexaria Bioscience Receives Approval From Independent Review Board for Pilot Study of Tirzepatide
Lexaria Bioscience Receives Approval From Independent Review Board for Pilot Study of Tirzepatide
Oct 3, 2024
10:54 AM EDT, 09/27/2024 (MT Newswires) -- Lexaria Bioscience ( LEXX ) said Friday that an unnamed independent review board has approved the firm's human pilot study 3 to evaluate a DehydraTECH-processed version of glucagon-like peptide, or GLP-1, plus glucose-dependent insulinotropic peptide, or GIP, tirzepatide in an oral dose format. The subject recruitment will start shortly and the first dosing...
Copyright 2023-2026 - www.financetom.com All Rights Reserved